轴向脊柱关节炎的高效MRI评分系统:一项可行性研究
前瞻性可行性研究纳入60例接受生物治疗的axSpA患者,在基线和治疗6个月时行骶髂关节和脊柱MRI,开发简化SPARCC评分(仅评估受累最重的3个层面/椎体而非6个)并与原版SPARCC评分比较。两种评分在治疗6个月后均显著改善(p < 0.001),简化评分与疾病活动标志物相关性不劣于或强于原版评分,中位评分下降71.4%–79.1%,评估时间由原版37分钟缩短至11分钟(p < 0.001)。结论认为简化SPARCC评分是有前景的研究工具,但需进一步验证以确认其更广泛的临床适用性。
要点
- 简化SPARCC评分仅评估受累最重的3个层面/椎体而非6个,中位评估时间由37分钟降至11分钟。
- 简化评分与疾病活动标志物相关性不劣于或强于原版评分,中位评分下降71.4%–79.1%。
- 简化脊柱SPARCC评分观察者间一致性最高,基线κ = 0.817、随访κ = 0.784。
核心结论
- 简化SPARCC MRI评分是有前景的axSpA疾病活动度评估研究工具,具有观察者间信度更优和评估时间显著缩短的优点,但需进一步验证以确认其更广泛的临床适用性。
研究设计与样本
- 前瞻性可行性研究,纳入60例接受生物治疗的axSpA患者,在基线和生物治疗开始后6个月行骶髂关节和脊柱MRI,开发简化SPARCC评分并与原版SPARCC评分比较,评估与临床指标和炎症标志物的相关性、观察者间一致性和对炎症变化的敏感性。
关键影像表现/征象
- 简化SPARCC评分聚焦于受累最重的3个层面/椎体,而非原版评分的6个。
- 两种评分在生物治疗开始6个月后均显示显著改善(p < 0.001)。
诊断标准与关键数值
- 简化SPARCC评分与原版评分的中位评分下降幅度为71.4%–79.1%。
- 简化脊柱SPARCC评分的观察者间一致性最高,基线κ = 0.817,随访κ = 0.784;所有评分的观察者间一致性为中等至几乎完全一致。
- 简化评分评估时间为11分钟,原版评分为37分钟,简化评分显著缩短评估时间(p < 0.001)。
临床应用与阅片要点
- 简化SPARCC评分可作为追踪axSpA患者生物治疗前后疾病活动变化的研究方法,评估时间由37分钟缩短至11分钟。
- 作者认为简化SPARCC评分是有前景的研究工具,需进一步验证以确认其更广泛的临床适用性。
局限性
- 原文结论指出需进一步验证以确认简化SPARCC评分更广泛的临床适用性。
- 原文要点指出需进一步验证以确认其常规临床实用性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To develop and assess the feasibility of a simplified Spondyloarthritis Research Consortium of Canada (SPARCC) MRI score for quantifying disease activity changes in patients with axial spondyloarthritis (axSpA) undergoing biological therapy, and compare its performance with the original SPARCC score.
MATERIALS AND METHODS: This prospective feasibility study included 60 axSpA patients receiving biological therapy. MRI examinations of the sacroiliac joints and spine were performed at baseline and six months after the initiation of biological therapy. The simplified SPARCC score, focusing on the three most affected slices/vertebrae instead of six, was developed and compared with the original SPARCC score. Both scores were correlated with clinical indices and inflammatory markers. Inter-reader agreement and sensitivity to inflammatory changes were evaluated to assess reliability and research utility.
RESULTS: Both scores showed significant improvement after six months of initiating biological therapy (p < 0.001). The simplified SPARCC scores correlated strongly with disease activity markers, comparable to or stronger than the original scores, with median score reductions of 71.4-79.1%. Inter-reader agreement was substantial to almost perfect for all scores, with simplified SPARCC spine score exhibiting the highest agreement (κ = 0.817 at baseline and 0.784 at follow-up). The simplified score significantly reduced assessment time compared with the original score (11 vs 37 min, p < 0.001).
CONCLUSION: The simplified SPARCC MRI score is a promising research tool for assessing disease activity in axSpA patients, with the advantages of improved inter-reader reliability and significantly reduced assessment time. Further validation is required to confirm its broader clinical applicability.
KEY POINTS: Question Can a simplified SPARCC MRI score reduce assessment time while reliably tracking disease activity changes? Findings The simplified SPARCC MRI score showed comparable sensitivity to change and reliability vs the original score, reducing mean assessment time from 37 min to 11 min. Clinical relevance The simplified SPARCC MRI score provides a faster, reliable research method for tracking axSpA activity changes, potentially improving clinical trial efficiency. Further validation is needed to confirm routine clinical utility.
引用
- Abdelrahman FI, Basha MAA, El-Sayad EAHF, et al. Time-efficient MRI scoring system for axial spondyloarthritis: a feasibility study. Eur Radiol. 2025. PMID: 40739054. doi:10.1007/s00330-025-11855-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。